SELP and myocardial infarction: A subgroup analysis of the Sertraline Antidepressant Heart Attack Trial (SADHART) was the first randomized, placebo-controlled trial that reported 24 weeks of treatment with sertraline, vs. placebo, was associated with a decrease in serum markers of platelet activation (P-selectin and β-TG) in 64 patients with MDD and acute coronary syndrome [21].